Ranbaxy would hire the services of Giuliani Partners to deal with the situation arising, after the banning of some of its products in the US market. It is recalled that the US Food and Drug Administration is not satisfied with the product quality of many of its drugs. It has, earlier banned 31 drugs in the US market. The Indian drug maker Ranbaxy is a major supplier of drugs to the US market.
The US Food and Drug Administration have put its report on its website. Some of the products of Indian medicine major, Ranbaxy do not conform to the safety standards set by the inspection agency of US. It has banned 31 drugs produced by Ranbaxy. The agency had not mentioned the name of Daiichi Sankyo, the Japanese firm which is in the process to buy the Indian medicine company in its report
The Food and Drug Administration (USFDA) is not satisfied with the quality of drugs produced by Ranbaxy. The agency has issued two letters to Indian drug major, warning it about the drug quality. The agency has raised questions on the quality of more than 30 generic drugs. The company is producing these drugs at its Paonta Sahib and Dewas plants.
Drug manufacturer, Matrix Laboratories has informed that US Food and Drug Administration (USFDA) has given tentative nod to market Lamivudine tablets (300 mg) and Tenofovir disoproxil fumarate tabl
The US Food and Drug Administration (USFDA) has given final approval to the US-based Zydus Pharmaceuticals, a subsidiary of Zydus Cadila to promote Ramipril capsules, in different potencies including 1.25 mg, 2.5 mg, 5 mg and 10 mg.
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor, which is used for treating high blood pressure and congestive heart failure.
Moreover, it is a prodrug and is converted to the active metabolite ramiprilat by liver esterase enzymes.
India's Advinus Therapeutics, a TATA-promoted life sciences research and development company, has announced a new collaboration with Genzyme and Medicines for Malaria Venture (MMV) to develop therapies to address the danger of emerging drug resistance that current anti-malarial treatments face.
The alliance seeks to develop new, improved treatments for specific patient groups most at risk for malaria, particularly pregnant women and infants.
after the banning of some of its products in the US market. It is recalled that the US Food and Drug Administration is not satisfied with the product quality of many of its drugs. It has, earlier banned 31 drugs in the US market. The Indian drug maker Ranbaxy is a major supplier of drugs to the US market. 
products of Indian medicine major, Ranbaxy do not conform to the safety standards set by the inspection agency of US. It has banned 31 drugs produced by Ranbaxy. The agency had not mentioned the name of Daiichi Sankyo, the Japanese firm which is in the process to buy the Indian medicine company in its report
produced by Ranbaxy. The agency has issued two letters to Indian drug major, warning it about the drug quality. The agency has raised questions on the quality of more than 30 generic drugs. The company is producing these drugs at its Paonta Sahib and Dewas plants.
India's Advinus Therapeutics, a TATA-promoted life sciences research and development company, has announced a new collaboration with Genzyme and Medicines for Malaria Venture (MMV) to develop therapies to address the danger of emerging drug resistance that current anti-malarial treatments face. 
